Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) traded down 4.8% during mid-day trading on Wednesday . The company traded as low as $8.59 and last traded at $8.67, with a volume of 675,165 shares trading hands. The stock had previously closed at $9.11.

Several analysts recently weighed in on the company. Canaccord Genuity reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, May 10th. Wells Fargo & Co. reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, May 10th. Piper Jaffray Cos. reissued an “overweight” rating and set a $15.00 price target on shares of Halozyme Therapeutics in a report on Thursday, June 9th. Finally, Jefferies Group reissued a “sell” rating and set a $6.75 price target on shares of Halozyme Therapeutics in a report on Tuesday, May 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Halozyme Therapeutics has an average rating of “Buy” and an average target price of $15.68.

The firm’s 50-day moving average is $9.01 and its 200 day moving average is $9.82. The company’s market capitalization is $1.12 billion.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. During the same period in the prior year, the company earned ($0.12) earnings per share. The business earned $42.50 million during the quarter, compared to the consensus estimate of $29.65 million. The business’s revenue was up 127.3% on a year-over-year basis. Equities analysts anticipate that Halozyme Therapeutics Inc. will post ($1.03) earnings per share for the current fiscal year.

Several institutional investors have added to or reduced their stakes in HALO. Nationwide Fund Advisors raised its position in Halozyme Therapeutics by 2.3% in the fourth quarter. Nationwide Fund Advisors now owns 69,817 shares of the biopharmaceutical company’s stock valued at $1,210,000 after buying an additional 1,563 shares in the last quarter. California State Teachers Retirement System raised its position in Halozyme Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 196,510 shares of the biopharmaceutical company’s stock valued at $3,406,000 after buying an additional 3,096 shares in the last quarter. California Public Employees Retirement System raised its position in Halozyme Therapeutics by 10.2% in the fourth quarter. California Public Employees Retirement System now owns 255,600 shares of the biopharmaceutical company’s stock valued at $4,430,000 after buying an additional 23,600 shares in the last quarter. ProShare Advisors LLC raised its position in Halozyme Therapeutics by 9.8% in the fourth quarter. ProShare Advisors LLC now owns 122,509 shares of the biopharmaceutical company’s stock valued at $2,123,000 after buying an additional 10,937 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in Halozyme Therapeutics by 5.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,785 shares of the biopharmaceutical company’s stock valued at $6,460,000 after buying an additional 18,940 shares in the last quarter.

Halozyme Therapeutics, Inc is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.